Sucampo Pharmaceuticals — Q3 2014 Earnings Presentation
33 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 6, 2014
Slide 1: Third Quarter 2014 Corporate Update and Financial Results
Third Quarter 2014 Corporate Update and Financial Results November 6, 2014 ¢ Fee ives TT
Slide 2: Silvia Taylor, Senior VP Investor Relations
Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications ¢ SUCAMPO The Science of Innovation v
Slide 3: Agenda
Agenda Introductions and Forward-Lookin: | Hl ig | ivi Statements Silvia Taylor | Corporate Update Peter Greenleaf | Pipeline Update Peter Lichtlen, M.D., Ph.D | Financial Performance Cary J. Claiborne } Closing Remarks Peter Greenleaf ¢ SUCAMPO : é ‘The Science of Innovation
Slide 4: Forward-Looking Statements
Forward-Looking Statements This pr n “forward-looking " as that term is defined in the Private Securities igation Reform Act of 1995. These st: are based on managi 's current ex; ions and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statem
Slide 5: Corporate Update
14 Corporate-Update Peter Greenleaf Chief Executive Officer e ? SUCAMPO The Science of Innovation
Slide 6: Q3 Key Highlights
Q3 Key Highlights 1. Continued strong financial performance 2. Significant progress in securing AMITIZA growth 3. Focused our efforts and strengthened organizational capabilities 4. Increasing focus on pipeline development we SUCAMPO The Science of Innovation
Slide 7: Continued Strong Financial Performance
Continued Strong Financial Performance Significant gains drove strong financial performance * Solid execution against our strategy + Raising full year 2014 guidance for net income excluding special items to $15 - $20M and earnings per share excluding special times to $0.35 - $0.45 per diluted share
Slide 8: Resolution of Our Patent Litigation
Resolution of Our Patent Litigation Resolved patent litigation on AMITIZA with Par Pharmaceuticals Received a Paragraph IV notice letter regarding an ANDA submitted by Dr. Reddy’s Laboratories + Will continue to vigorously defend IP of AMITIZA we SUCAMPO . ‘The Science of innovation
Slide 9: Improving and Strengthening Partnerships
Improving and Strengthening Partnerships Strengthened Partnership with Takeda + Signed a global license, development, commercialization and supply agreement for AMITIZA for all global markets except Japan and China + Amended our existing collaboration and license agreement covering North America Neg
Slide 10: Global AMITIZA Approvals and Regulatory Filings
Global AMITIZA Approvals and Regulatory Filings MRP in Europe cic UK. Canada CIC and OIC CIC 012) i (started 10/31/14) 3 Switzerland CIC (2009) OIC (2014) Us. CIC (2006) IBS-C (2008) OIC (2013) Latin America TBD Takeda has rights to all markets except Japan (Abbott) and China $ SUCAMPO The Sei
Slide 11: Proven and Experienced Management Team
Proven and Experienced Management Team Corwen idl Homo Astrazeneca centocor eter Kiener, D.Phil Ambrx Se BLE ORE? Bristol-Myers Squibb idl Zyngenia ‘Peter Lichtlen, M.D., Ph.D. Chief Medical Oicer | Alcon ESBATech Matthias Alder Expanded Management CYTOS micr@met Cooley Team with or BATH Considerabl
Slide 12: Clinical Development Strategy - Update
Clinical Development Strategy - Update Clinical Development is Company’s Core Focus + Assessed each pipeline asset: scientific, regulatory, and commercial criteria + Decisions made on each asset's development plan + Shortened time to market across all compounds + Increased transparency around pipeli
Slide 13: Peter Lichtlen, M.D., Ph.D., Chief Medical Officer
Peter Lichtlen, M.D., Ph.D. Chief Medical Officer SUCAMPO The Science of Innovation AS
Slide 14: Accelerating Additional Formulations for AMITIZA
Accelerating Additional Formulations for AMITIZA Strong Partnership is Key to Success * Takeda funding 100% of costs for alternate formulation work, 70% of costs for pediatric functional constipation program Development Timeline: Lubiprostone — Alternate Formulation + Phase 3: 2H 15 | Oe PFC Phase 3
Slide 15: Cobiprostone for NERD (Non-Erosive Reflux Disease)
Cobiprostone for NERD {Non-Erosive Reflux Disease) NERD + Subtype of gastro-esophagael reflux disease (GERD) + Will begin a development program for cobiprostone to treat NERD * ~7-18 million PPI - refractory NERD patients in North America Fatroanoe gd Flas Lim Faire on PP gd 20% Development Timeline
Slide 16: Cobiprostone for Oral Mucositis
Cobiprostone for Oral Mucositis Oral Mucositis + Oral mucositis is a debilitating side effect of radiation therapy and chemotherapy + Causes large ulcers inside an individual's mouth Development Timeline: + Phase 2: 1H 15 + Phase 3: 1H 17 + Regulatory Filing: 2H 18 + Regulatory Approval: 2H 19 e 9 S
Slide 17: Ion Channel Activator for Lumbar Spinal Stenosis
lon Channel Activator for Lumbar Spinal Stenosis (LSS) Lss + Degenerative change in lumbar spine; unmet medical need with limited treatment options globally + More than 400,000 Americans, most >60 years of age, may be suffering from symptoms caused by lumbar spinal stenosis + Will move forward with
Slide 18: Unoprostone Isopropyl for Retinitis Pigmentosa
tapprostone Isopropyl for Retinitis Pigmentosa Retinitis Pigmentosa + Caused by gene mutations (variations) inherited from one or both parents + Begins with degeneration of rods, followed by progressive and irreversible death of cones leading to blindness. + RP affects about 1.5 million people world
Slide 19: Unoprostone Isopropyl for Geographic Atrophy
Unoprostone Isopropyl for Geographic Atroph (GAY! Age Related cult Geconcraton (AMD) Geographic Atrophy / Age Related Macular Degeneration + Dry AMD is the most common type of age related macular degeneration + More than a million patients are suffering from its advanced form, geographic atrophy, in
Slide 20: At-A-Glance: Sucampo Pipeline
At-A-Glance: Sucampo Pipeline CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT COMPLETED WIN PROGRESS / PROJECTED START ¢ > SUCAMPO 20
Slide 21: Diversify Our Science
Diversify Our Science Commenced external assessment of new therapeutic areas and targets + Build from our core in ophthalmology and GI * Consider both early and mid-to-late stage assets we SUCAMPO The Science of Innovation
Slide 22: Financial Performance
14 Performance-Update Cary J. Claiborne Chief Financial Officer é > SUCAMPO The Science of Innovation
Slide 23: Financial Performance ($M, Excluding Special Items)
ce ($M, Excluding)Special $0.20 $8.6 $6.3 Q3-14 YTD-14 Q3-14 YTD-14 Net Income EPS SUCAMPO = The Science of Innovation we
Slide 24: Financial Performance ($M, GAAP Earnings)
ial Performance ($M, GAAP Earnings) $0.09 $3.8 | | _ $1.5 $0.03 j — a, : Q3-14 YTD-14 Q3-14 YTD-14 Net Income EPS ¢$ sucAMPO 24 @ The Sstenes ol mension
Slide 25: U.S. Net Sales ($M)
S. Net Sales* ($M) AMITIZA a Q3-13 Q3-14 YTD-2013 YTD-2014 Driven by 4% TRx Growth & ¢ SUCAMPO 25 ha ic) Ta or ay sakura é The Science of innovation
Slide 26: Q3 Revenue Highlights ($M)
Q3 Revenue Highlights ($M) +118% Q3-13 Q3-14 Q3-13 Q3-14 Q3-13 Q3-14 Product Royalty Product Sales Total Revenue Revenue Revenue $ sucampo 28 The Science of Innovation
Slide 27: Year-to-Date Operating Expenses
$18.6 25%) = $16.0 $14.5 $14.7 hee $11.5 $9.5 : YTD-13 YTD-14 YTD-13 YTD-14 YTD-13 YTD-14 YTD-13 YTD-14 Cost of Goods R&D Expenses G&A Expenses S&M Expenses Sold e y ? SUCAMPO The Science of Innovation
Slide 28: Updated Financial Guidance
Updated Financial Guidance Updated 2014 Financial Guidance Net Income Excluding Special Items $15 - $20M EPS Excluding Special Items $0.35 - $0.45 SUCAMPO = The Science of Innovation we
Slide 29: Peter Greenleaf, Chief Executive Officer
Peter Greenleaf Chief Executive Officer SUCAMPO The Science of Innovation AS
Slide 30: Upcoming Milestones
Upcoming Milestones Expected Tg Global partnership agreement ¥ Update on AMITIZA alternate formulation and PFC development v File AMITIZA (CIC and OIC) for approval in Canada y Initiate MRP to secure approval for AMITIZA (CIC) in additional European markets q Decision on ion channel activator progra
Slide 31: Vision: Globally, Fully Integrated Pharmaceutical Company
ision: Globally, Fully Integrated aceutical Company. We will continue to execute on our strategy Secure The Foundation Seated Build The Growth Platform = Strengthen our overall capabilities = Secure AMITIZA franchise and drive = Advance AMITIZA Tite cycle management global growth 2 ppumize a ' inves
Slide 32: o
o 2 SUCAMPO The Science of Innovation
Slide 33: References
References Radiograph from Borowitz - Pediatric Constipation article on Medscape website; accessed 09.19.13, 2. Data from US Census Bureau website (http /factfinder2, census qovifacesitableservicesiisflages/productview xhtmI?sre=bkmk) 3, Sucampo data on file 4. Trott Aet al. Mucositis incidence, sev
Sucampo Pharmaceuticals — Q3 2014 Earnings Presentation on 6ix